Literature DB >> 15258776

Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation in pathologic myopia.

Faik Gelisken1, Werner Inhoffen, Alexander Hermann, Salvatore Grisanti, Karl Ulrich Bartz-Schmidt.   

Abstract

BACKGROUND: To report long-term functional and morphological outcome of verteporfin photodynamic therapy (PDT) for classic extrafoveal choroidal neovascularisation (CNV) secondary to pathologic myopia.
METHODS: This retrospective case series included three eyes of three consecutive patients with classic extrafoveal CNV secondary to pathologic myopia, who underwent PDT at a tertiary retinal referral centre. Change in visual acuity and fluorescein leakage was the main outcome criteria.
RESULTS: The patients were followed up an average of 36 months (33-40 months). In all eyes increase of visual acuity (one eye 1 ETDRS line, two eyes 2 ETDRS line) and no fluorescein leakage of the CNV were seen.
CONCLUSIONS: PDT can achieve long-term improvement of the visual acuity and morphological stability in selected cases with classic extrafoveal CNV in pathologic myopia. Large scale randomised studies are warranted for assessment of the benefit of PDT in such eyes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15258776     DOI: 10.1007/s00417-004-0949-0

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  6 in total

1.  Pathologic myopia: where are we now?.

Authors:  Yasuo Tano
Journal:  Am J Ophthalmol       Date:  2002-11       Impact factor: 5.258

2.  Photodynamic therapy for juxtafoveal choroidal neovascularization in myopic eyes.

Authors:  Salomon Y Cohen; Alexandra Bulik; Lise Dubois; Gabriel Quentel
Journal:  Am J Ophthalmol       Date:  2003-08       Impact factor: 5.258

3.  Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.

Authors: 
Journal:  Ophthalmology       Date:  2001-05       Impact factor: 12.079

4.  Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.

Authors:  Kevin J Blinder; Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donato; Hilel Lewis; Jennifer I Lim; Ugo Menchini; Joan W Miller; Jordi M Mones; Michael J Potter; Constantin Pournaras; Al Reaves; Philip Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenberg; Lawrence J Singerman; Jason S Slakter; H Andrew Strong; Gianni Virgili; George A Williams
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

5.  Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment.

Authors:  M Secrétan; D Kuhn; G Soubrane; G Coscas
Journal:  Eur J Ophthalmol       Date:  1997 Oct-Dec       Impact factor: 1.922

6.  Natural history of choroidal neovascularization in degenerative myopia.

Authors:  M P Avila; J J Weiter; A E Jalkh; C L Trempe; R C Pruett; C L Schepens
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

  6 in total
  8 in total

1.  Photodynamic therapy with verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results including juxtafoveal and extrafoveal CNV.

Authors:  Joachim Wachtlin; Andrea Stroux; Andreas Wehner; Heinrich Heimann; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-11       Impact factor: 3.117

Review 2.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

Review 3.  [Pseudoxanthoma elasticum].

Authors:  M S Ladewig; C Götting; C Szliska; P C Issa; H-M Helb; I Bedenicki; H P N Scholl; F G Holz
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

4.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Amy L Wong; David T L Liu; Dennis S C Lam
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

5.  Co-existent choroidal neovascular membrane and macular hole in pathologic myopia: a long follow-up clinical outcome and literature review.

Authors:  Zhi-Qing Chen; Ji-Jian Lin; Pan-Pan Ye; Li Zhang; Xiao-Yun Fang
Journal:  Int J Ophthalmol       Date:  2013-12-18       Impact factor: 1.779

6.  Photodynamic therapy with verteporfin for choroidal neovascularization associated with angioid streaks.

Authors:  Heinrich Heimann; Faik Gelisken; Joachim Wachtlin; Andreas Wehner; Michael Völker; Michael H Foerster; Karl Ulrich Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-06-10       Impact factor: 3.117

Review 7.  Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application.

Authors:  Yan Zhang; Qian Han; Yusha Ru; Qiyu Bo; Rui Hua Wei
Journal:  Drug Des Devel Ther       Date:  2015-07-02       Impact factor: 4.162

8.  Management of coexistent choroidal neovascular membrane and macular hole with serous detachment in a case of pathological myopia: challenges and dilemmas.

Authors:  Naresh Babu Kannan; Sagnik Sen; Obuli Ramachandran; Kim Ramasamy
Journal:  BMJ Case Rep       Date:  2020-03-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.